泛癌分析:生长抑素受体表达肿瘤作为肽受体成像与治疗潜在靶点的临床与遗传特征
该研究基于癌症基因组图谱(TCGA)中32种癌症类型、10701例受试者的数据,分析生长抑素受体2(SST2)表达与临床及遗传特征的相关性,以嗜铬细胞瘤和副神经节瘤(PCPG)SST2表达中位数定义「高SST2肿瘤」。结果显示除PCPG外31种亚型中8种有超过5%的高SST2肿瘤,低级别胶质瘤(LGG)比例最高,其次为乳腺浸润癌(BRCA);LGG中高SST2与良好预后显著相关,三阴性乳腺癌中高SST2与不良预后呈关联趋势。
要点
- 以PCPG的SST2表达中位数为阈值定义高SST2肿瘤,除PCPG外31种亚型中8种高SST2肿瘤占比超过5%。
- LGG的高SST2肿瘤比例最高,其次为BRCA;LGG中IDH1突变与高SST2状态显著相关。
- LGG患者中高SST2状态与良好预后显著相关,三阴性乳腺癌中高SST2状态与不良预后呈关联趋势。
核心结论
- 多种癌症亚型中观察到广泛的SST2表达,SST2表达水平与基因组和临床特征显著相关,尤其在LGG和BRCA中。
- 这些发现扩展了将PRRT及SST成像适应证多样化的知识基础。
研究设计与样本
- 基于癌症基因组图谱(TCGA)中代表32种癌症类型的10701例受试者数据,评估SST表达水平。
- 以PCPG样本的SST2表达中位数作为阈值定义「高SST2肿瘤」,并进行泛癌临床与遗传特征和SST2水平的相关分析。
- 采用Cox比例回归分析评估SST2在各癌症亚型中的预后价值。
主要发现
- 构建了与临床病理特征和基因组改变相关的SST表达模式资源,并提供可交互分析各癌症类型SST表达模式的工具。
- 除PCPG外,31种癌症亚型中有8种的高SST2表达肿瘤占比超过5%。
- LGG的高SST2肿瘤比例最高,其次为BRCA;LGG的SST2水平随肿瘤分级和组织学不同而异。
- IDH1突变与高SST2状态显著相关;BRCA中SST2水平随激素受体状态不同而异。
- LGG患者中高SST2状态与良好预后显著相关;三阴性乳腺癌受试者中高SST2状态与不良预后呈关联趋势。
关键数值与推荐
- 以PCPG样本的SST2表达中位数作为定义「高SST2肿瘤」的阈值。
- 高SST2肿瘤定义为SST2表达水平高于PCPG样本SST2表达中位数的肿瘤。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Although somatostatin receptor (SST) is a promising theranostic target and is widely expressed in tumors of various organs, the indication for therapies targeting SST is limited to typical gastroenteropancreatic neuroendocrine tumors (NETs). Thus, broadening the scope of the current clinical application of peptide receptor radiotherapy (PRRT) can be supported by a better understanding of the landscape of SST-expressing tumors. METHODS: SST expression levels were assessed in data from The Cancer Genome Atlas across 10,701 subjects representing 32 cancer types. As the major target of PRRT is SST subtype 2 (SST2), correlation analyses between the pan-cancer profiles, including clinical and genetic features, and SST2 level were conducted. The median SST2 expression level of pheochromocytoma and paraganglioma (PCPG) samples was used as the threshold to define "high-SST2 tumors." The prognostic value of SST2 in each cancer subtype was evaluated by using Cox proportional regression analysis. RESULTS: We constructed a resource of SST expression patterns associated with clinicopathologic features and genomic alterations. It provides an interactive tool to analyze SST expression patterns in various cancer types. As a result, eight of the 31 cancer subtypes other than PCPG had more than 5% of tumors with high-SST2 expression. Low-grade glioma (LGG) showed the highest proportion of high-SST2 tumors, followed by breast invasive carcinoma (BRCA). LGG showed different SST2 levels according to tumor grade and histology. IDH1 mutation was significantly associated with high-SST2 status. In BRCA, the SST2 level was different according to the hormone receptor status. High-SST2 status was significantly associated with good prognosis in LGG patients. High-SST2 status showed a trend for association with poor prognosis in triple-negative breast cancer subjects. CONCLUSION: A broad range of SST2 expression was observed across diverse cancer subtypes. The SST2 expression level showed a significant association with genomic and clinical aspects across cancers, especially in LGG and BRCA. These findings extend our knowledge base to diversify the indications for PRRT as well as SST imaging.
引用
- Lee H, Suh M, Choi H, et al. A pan-cancer analysis of the clinical and genetic portraits of somatostatin receptor expressing tumor as a potential target of peptide receptor imaging and therapy. EJNMMI Res. 2020. PMID: 32335823. doi:10.1186/s13550-020-00632-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。